A Phase III, Randomized, Double-Blind, Placebo Controlled, Multi-Center Study of the Safety and Efficacy of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women.

Trial Profile

A Phase III, Randomized, Double-Blind, Placebo Controlled, Multi-Center Study of the Safety and Efficacy of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women.

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Jan 2012

At a glance

  • Drugs Testosterone (Primary)
  • Indications Decreased libido
  • Focus Registrational; Therapeutic Use
  • Acronyms BLOOM; BLOOM-1
  • Most Recent Events

    • 14 Dec 2011 Primary endpoint 'Sexual-desire' has not been met.
    • 14 Dec 2011 Primary endpoint 'Sexual-satisfaction' has not been met.
    • 14 Dec 2011 Primary endpoint 'Assessment-scale-scores' has not been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top